We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glycine Treatment of Prodromal Symptoms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00268749
First Posted: December 22, 2005
Last Update Posted: March 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Stanley Medical Research Institute
Information provided by (Responsible Party):
Yale University
  Purpose
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Condition Intervention Phase
Schizophrenia Drug: glycine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glycine Treatment of Prodromal Symptoms

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Scale Of Prodromal Symptoms total score [ Time Frame: 8 weeks ]

Enrollment: 10
Study Start Date: July 2002
Study Completion Date: November 2004
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: glycine
0.8 g/kg/day

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 14-35
  • meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

  • current antipsychotic medication
  • more than 4 weeks of antipsychotic medication lifetime
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268749


Sponsors and Collaborators
Yale University
Stanley Medical Research Institute
Investigators
Principal Investigator: Scott W Woods, MD Yale University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00268749     History of Changes
Other Study ID Numbers: 02T-175
First Submitted: December 20, 2005
First Posted: December 22, 2005
Last Update Posted: March 29, 2012
Last Verified: March 2012

Additional relevant MeSH terms:
Schizophrenia
Prodromal Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Signs and Symptoms
Glycine
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs